Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, entitled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension,” is currently available online and will be included in a future printed edition of the European Respiratory Journal, the flagship scientific journal of the European Respiratory Society.
“We are excited to share some of the preclinical foundations for the seralutinib program in such a high impact scientific journal,” said Faheem Hasnain, Co-Founder, Chairman and Chief Executive Officer of Gossamer Bio. “The studies included in the publication are part of the reason why we, along with the broader PAH community, are eagerly anticipating the topline results of the Phase 2 TORREY Study in the fourth quarter of this year.”
The article can be accessed via a link from the Posters and Publications section of the Gossamer website (https://www.gossamerbio.com/pipeline/posters-and-publications/) or directly via the European Respiratory Journal website (https://erj.ersjournals.com/).
Article Information
- Journal: European Respiratory Journal
- Title: Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension
- DOI: 10.1183/13993003.02356-2021
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
Forward-Looking Statements
Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: expectations on the timing of data readouts from our clinical studies, including the timing of topline results for the Phase 2 TORREY study for seralutinib; the potential benefits of seralutinib based on preclinical data; and the future in print publication of the article mentioned herein. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer’s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the ongoing COVID-19 pandemic, including clinical trial delays and clinical site staff shortages; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for its product candidates; interim results do not necessarily predict final results and one or more of the outcomes may materially change as the trial continues and more patient data become available and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for its product candidates; Gossamer’s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005043/en/
Contacts
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
